-
公开(公告)号：US20180042968A1
公开(公告)日：2018-02-15
申请号：US15791205
申请日：2017-10-23
CPC分类号： A61K35/30 , A61K35/12 , A61K35/51 , A61K2035/124 , C12N5/0618 , C12N2501/13 , C12N2501/385 , C12N2506/1369
摘要： The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.
-
公开(公告)号：USD793944S1
公开(公告)日：2017-08-08
申请号：US29543915
申请日：2015-10-29
申请人： Judy Genshaft , Paul R. Sanberg
设计人： Judy Genshaft , Paul R. Sanberg
-
公开(公告)号：US09051386B2
公开(公告)日：2015-06-09
申请号：US14220714
申请日：2014-03-20
CPC分类号： C07K14/4703 , A61K38/00 , Y02A50/471
摘要： A method of treating inflammation by administering a therapeutically effective amount of a human immunosuppressant protein (HISP) to a subject is presented. The inventors have discovered a novel immunosuppressive protein purified from the supernatant of hNT cell culture. The immunosuppressant protein has a molecular weight of about 40-100 kDa, an isoelectric point of about 4.4, a net ionic charge and is capable of suppressing T-cell activation, T-cell proliferation and the production of IL-2. This protein can be used in treating inflammation, preventing graft rejection after transplantation, treating autoimmune diseases and suppressing allergic responses as well as other uses.
摘要翻译： 提出了通过向受试者施用治疗有效量的人免疫抑制蛋白（HISP）来治疗炎症的方法。 本发明人发现了从hNT细胞培养物的上清液中纯化的新型免疫抑制蛋白。 免疫抑制蛋白具有约40-100kDa的分子量，约4.4的等电点，净离子电荷，并且能够抑制T细胞活化，T细胞增殖和IL-2的产生。 该蛋白质可用于治疗炎症，预防移植后的移植排斥反应，治疗自身免疫疾病和抑制过敏反应以及其他用途。
-
公开(公告)号：US20140369983A1
公开(公告)日：2014-12-18
申请号：US14336621
申请日：2014-07-21
申请人： Paul R. Sanberg , Alison E. Willing
发明人： Paul R. Sanberg , Alison E. Willing
IPC分类号： A61K35/14 , C12N5/0786
CPC分类号： A61K35/15 , A61K35/44 , A61K35/51 , A61K2035/124 , C12N5/0634 , C12N5/0645
摘要： The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.
摘要翻译： 本发明涉及用于治疗缺血性疾病和病症，特别是心肌，CNS /脑和肢体缺血的组合物和方法。 更具体地，本发明提供了通过从需要治疗的个体施用从血液（包括脐带血，外周血或骨髓）获得的单核细胞来治疗疾病的方法，其中在具体时间点向个体施用药物 确定提供治疗功效。 在一个实施方案中，细胞用于注射到缺血心肌中用于治疗心绞痛。
-
公开(公告)号：US20080279835A1
公开(公告)日：2008-11-13
申请号：US12117197
申请日：2008-05-08
申请人： Robert J. Henning , Paul R. Sanberg
发明人： Robert J. Henning , Paul R. Sanberg
CPC分类号： A61K35/51
摘要： A method of treating acute myocardial infarction has the steps of providing human umbilical cord blood cells (HUCBC); and administering the HUCBC to the individual with the acute myocardial infarction at particular time intervals after said myocardial infarction. Preferably the intervals are about one to about three hours or about 12 to about 48 hours after the acute myocardial infarction.
摘要翻译： 治疗急性心肌梗死的方法有以下步骤：提供人脐血细胞（HUCBC）; 并在所述心肌梗塞后的特定时间间隔内将HUCBC给予患有急性心肌梗死的个体。 优选地，间隔在急性心肌梗塞后约1至约3小时或约12至约48小时。
-
公开(公告)号：US07388076B2
公开(公告)日：2008-06-17
申请号：US10621061
申请日：2003-07-16
CPC分类号： C07K14/4703 , A61K38/00 , Y02A50/471
摘要： A method for purifying an immunosuppressant protein (HISP) has the steps of obtaining supernatant from hNT cells; exposing the supernatant to preparative polyacrylamide gel electrophoresis to produce 20 isoelectric fractions, including active isoelectric fraction #10; placing the active isoelectric fraction on a Blue Sepharose column to bind albumin; and collecting the free fraction containing the concentrated, isolated HISP. Also disclosed is a method of treating inflammation, using an effective amount of an HISP. The HISP is anionic, has a molecular weight of 40-100 kDa, an isoelectric point of about 4.8 and is obtained from the supernatant of hNT cells, but not from NCCIT embryonal carcinoma cells, T98G glioblastoma cells or THP-1 monocytic leukemia cells. HISP can maintain T cells in a quiescent G0/G1 state without lowering their viability. HISP loses activity when treated with heat, pH2, pH11, or mixed with trypsin or carboxypeptidase, but not with neuraminidase. HISP can suppress proliferation of responder peripheral blood mononuclear cells in allogeneic mixed lymphocyte cultures; HISP can suppress T-cell proliferation and IL-2 production in response to phorbol 12-myristate 13-acetate (PMA), ionomycin and concanavalin-A. HISP does not bind to heparin-sepharose CL-B gel; or to albumin-binding resin Blue Sepharose. HISP is concentrated with YM10 ultrafiltration. HISP does not act through the T-cell receptor-CD3 complex or via altered accessory signal cells. A method of treating inflammation comprises administering an effective amount of hNT neuronal cells.
摘要翻译： 纯化免疫抑制蛋白（HISP）的方法具有从hNT细胞获得上清液的步骤; 将上清液暴露于制备型聚丙烯酰胺凝胶电泳以产生20个等电点，包括活性等电点＃10; 将活性等电点部分置于蓝色琼脂糖凝胶柱上以结合白蛋白; 并收集含有浓缩，分离的HISP的游离级分。 还公开了使用有效量的HISP治疗炎症的方法。 HISP是阴离子型的，分子量为40-100kDa，等电点约为4.8，从hNT细胞的上清液获得，而不是来自NCCIT胚胎癌细胞，T98G胶质母细胞瘤细胞或THP-1单核细胞白血病细胞。 HISP可以将T细胞维持在静止状态，而不降低其活力。 当用热，pH2，pH11处理或与胰蛋白酶或羧肽酶混合时，HISP失去活性，但不与神经氨酸酶混合。 HISP可以抑制同种异体混合淋巴细胞培养物中应答者外周血单核细胞的增殖; HISP可以抑制佛波醇12-肉豆蔻酸酯13-乙酸酯（PMA），离子霉素和伴刀豆素A的T细胞增殖和IL-2产生。 HISP不结合肝素 - 琼脂糖CL-B凝胶; 或白蛋白结合树脂蓝色琼脂糖。 HISP集中在YM10超滤。 HISP不通过T细胞受体-CD3复合物或通过改变的附属信号细胞起作用。 治疗炎症的方法包括施用有效量的hNT神经元细胞。
-
27.发明授权公开(公告)号：US06649160B1
公开(公告)日：2003-11-18
申请号：US09661352
申请日：2000-09-14
IPC分类号： A01N6300
CPC分类号： C12N5/0683 , A61K35/12 , A61K35/30 , A61K35/48 , A61K2035/122 , C12N5/0618 , C12N2502/246
摘要： A method of producing a sustained localized immunosuppressive effect in localized tissues is achieved by transplanting Sertoli cells proximate to the tissue.
摘要翻译： 通过移植靠近组织的Sertoli细胞来实现在局部组织中产生持续的局部免疫抑制作用的方法。
-
28.发明授权Methods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix core 失效制备具有生物相容性护套和生物相容性基质芯的免疫分离可植入载体的方法
公开(公告)号：US5874099A
公开(公告)日：1999-02-23
申请号：US449837
申请日：1995-05-24
申请人： Keith E. Dionne , Dwaine F. Emerich , Diane Hoffman , Paul R. Sanberg , Lisa Christenson , Orion D. Hegre , David W. Scharp , Paul E. Lacy , Patrick Aebischer , Alfred V. Vasoohcellos , Michael J. Lysaght , Frank T. Gentile
发明人： Keith E. Dionne , Dwaine F. Emerich , Diane Hoffman , Paul R. Sanberg , Lisa Christenson , Orion D. Hegre , David W. Scharp , Paul E. Lacy , Patrick Aebischer , Alfred V. Vasoohcellos , Michael J. Lysaght , Frank T. Gentile
IPC分类号： A61F2/02 , A61K9/00 , A61K9/48 , A61K9/50 , A61K35/12 , A61K35/30 , A61K35/39 , A61K38/18 , A61K39/395 , A61K47/36 , A61K48/00 , A61L27/00 , C12N5/00 , C12N5/071 , C12N5/077 , A61K9/14
CPC分类号： A61K9/0092 , A61K35/12 , A61K35/30 , A61K35/39 , A61K38/185 , A61K48/00 , A61K9/0024 , A61K9/4816 , C12N5/0012 , C12N5/0062 , C12N5/0614 , C12N5/0656 , C12N5/0677 , A61K2035/126 , A61K2035/128 , C12N2510/02 , Y10S514/814 , Y10S514/866
摘要： A method of forming an implantable and retrievable immunoisolatory vehicles is disclosed, the method comprising the steps of first forming a core comprising a volume of at least 1 .mu.l and at least 10.sup.4 cells capable of providing a biologically active product or metabolic or immunologic function, said cells being dispersed in a biocompatible hydrogel or extracellular matrix, and then forming around the core a surrounding external biocompatible thermoplastic or hydrogel jacket free of said cells projecting externally thereof, said jacket having molecular weight cutoff permitting passage of molecules to and from the core through said jacket to provide said biologically active product or function.
摘要翻译： 公开了一种形成可植入和可回收的免疫隔离剂的方法，所述方法包括以下步骤：首先形成包含至少1μl的体积和至少能够提供生物活性产物或代谢或免疫功能的至少104个细胞的核心， 所述细胞分散在生物相容的水凝胶或细胞外基质中，然后在核心周围形成周围的外部生物相容性热塑性或水凝胶套，所述周围的外部生物相容性热塑性或水凝胶护套不含外部突出的所述细胞，所述护套具有分子量截留允许分子通过和穿过芯通过 所述护套提供所述生物活性产品或功能。
-
公开(公告)号：US5827736A
公开(公告)日：1998-10-27
申请号：US782509
申请日：1997-01-09
IPC分类号： A61K35/12 , A61K35/39 , A61K35/48 , A61K38/00 , C12N5/071 , C12N5/16 , C12N15/00 , C12N5/00 , C12N5/02
CPC分类号： C12N5/0683 , A61K35/39 , A61K35/48 , C12N5/16 , A61K2035/122 , A61K35/12 , A61K38/00
摘要： A purified and isolated Sertoli cell and secretory cell hybrid, or an aggregate of these two cells, wherein the secretory cells preferably are pancreatic islet cells and chromaffin cells characterized by being a) capable of survival in situ after transplantation; b) able to provide immunoprotection for the hybrid cells when transplanted; and c) able to provide a mechanism for prolonged viability and cellular functionality of the transplanted hybrid cells wherein the hybrid maintains both the immunoprotection characteristics of the Sertoli cell and the secretory function of the secretory cell.
摘要翻译： 纯化和分离的Sertoli细胞和分泌细胞杂交体或这两种细胞的聚集体，其中分泌细胞优选是胰岛细胞和嗜铬细胞，其特征在于a）能够在移植后就地存活; b）能够在移植时为杂交细胞提供免疫保护; 和c）能够提供移植杂交细胞的延长活力和细胞功能的机制，其中所述杂合物维持所述Sertoli细胞的免疫保护特征和分泌细胞的分泌功能。
-
公开(公告)号：US08784802B2
公开(公告)日：2014-07-22
申请号：US13063456
申请日：2009-09-14
IPC分类号： A61K35/14
CPC分类号： A61K35/15 , A61K35/44 , A61K2035/124 , C12N5/0634 , C12N5/0645
摘要： The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.
摘要翻译： 本发明涉及用于治疗缺血性疾病和病症，特别是心肌，CNS /脑和肢体缺血的组合物和方法。 更具体地，本发明提供了通过从需要治疗的个体施用从血液（包括脐带血，外周血或骨髓）获得的单核细胞来治疗疾病的方法，其中在具体时间点向个体施用药物 确定提供治疗功效。 在一个实施方案中，细胞用于注射到缺血心肌中用于治疗心绞痛。
-
-
-
-
-
-
-
-
-
搜索结果
56 条记录 (耗时 0.043 秒)
